Customised design of antisense oligonucleotides targeting EGFR driver mutants for personalised treatment of non-small cell lung cancer
This study was funded by Singapore's Ministry of Health (NMRC/OFIRG/MOH-000643-00, OFIRG21nov-0068, NMRC/OFLCG/002-2018, OFYIRG22jul-0034), National Research Foundation (NRF-NRFI08-2022, NRF-CRP22-2019-0003, NRF-CRP23-2019-0004), A∗STAR, and Ministry of Education.
Authors
- Brendon Zhi Jie Yeo (ORCID: https://orcid.org/0000-0002-2120-0250)
- Migara Kavishka Jayasinghe
- Boon Cher Goh (ORCID: https://orcid.org/0000-0002-4107-102X)
- Cao Dai Phung (ORCID: https://orcid.org/0000-0001-5771-2664)
- Eric Yeo
- Wai Leong Tam (ORCID: https://orcid.org/0000-0003-2365-5264)
- Minh T. N. Le (ORCID: https://orcid.org/0000-0002-6077-1566)
- Rebecca Carissa Prajogo (ORCID: https://orcid.org/0009-0005-8578-8603)
- Yuan Ju
- Daniel Shao-Weng Tan (ORCID: https://orcid.org/0009-0005-4021-2176)
- Trinh T T Tran
Institutions
- Agency for Science, Technology and Research (SG)
- National University of Singapore (SG)
- National University Cancer Institute, Singapore (SG)
- National Cancer Centre Singapore (SG)
- Genome Institute of Singapore (SG)
Publication Details
- Journal
- EBioMedicine
- Published
- 2024-09-19
- DOI
- https://doi.org/10.1016/j.ebiom.2024.105356
- Citations
- 10
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 4.19
Funders
- National Research Foundation
- Agency for Science, Technology and Research
- Ministry of Health -Singapore
- National Research Foundation Singapore
- Ministry of Education - Singapore
- Medical Research Council
- National Medical Research Council